Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On June 30, 2025, Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on peptide-based therapeutics, announced the nomination of PN-477, a triple agonist peptide targeting GLP-1, GIP, and GCG receptors, for obesity treatment
NABL Lab Tested Quality : Tested for purity, safety and consistency through NABL accredited laboratories ensuring trusted quality, reliability and manufacturing standards
Contact your GP or NHS 111 within 2448 hours if you notice: New or worsening abdominal pain that differs from typical Ozempic side effects Persistent constipation lasting more than a few days despite dietary measures Minor or intermittent rectal bleeding Unexplained weight loss beyond expected therapeutic effects Gastrointestinal symptoms that do not improve after 23 weeks on a stable dose Difficulty managing blood glucose levels due to altered eating patterns Right upper abdominal pain, fever or yellowing of skin/eyes (possible gallbladder problems) For routine concerns , such as mild nausea or questions about managing side effects, patients can contact their diabetes specialist nurse or practice pharmacist for advice
BPC 157 and blood vessels
PMC: Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss. New England Journal of Medicine: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. PMC: Who Wins the Battle Against Obesity
However, for the most part, blue urine is a result of foods containing blue coloring, or from the use of medication, including indomethacin pain relief medication, amitriptyline antidepressants, cimetidine inhibitors and propofol anesthesia medication
